ProCE Banner Activity

Current Treatment Landscape and Promising New Therapies for Patients With Prurigo Nodularis

Clinical Thought

While prurigo nodularis (PN) may be a result of several underlying conditions, it is a distinct clinical entity that may persist despite removal of the underlying cause. Several promising agents in phase III trials may provide significant long-term relief.

Released: September 15, 2022

Expiration: September 14, 2023

Begin Activity



Benjamin Ungar

Benjamin Ungar, MD

Assistant Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York


This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.; Incyte Corporation; Novartis Pharmaceuticals Corporation; and Sanofi and Regeneron Pharmaceuticals.

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Provided by

ProCE Banner
ProCE Banner


Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Sanofi and Regeneron Pharmaceuticals

Target Audience

NPs and PAs


Benjamin Ungar, MD: consultant/advisor/speaker: Arcutis; researcher: Incyte, Pfizer, Rapt Therapeutics.


ClinicalThought Commentary

Additional Information

Program Medium

This program has been made available online.